California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry

被引:0
|
作者
Feuchtbaum, L
Lorey, F
Faulkner, L
Sherwin, J
Currier, R
Bhandal, A
Cunningham, G
机构
[1] Calif Dept Hlth Serv, Genet Dis Branch, Richmond, CA 94804 USA
[2] Calif Dept Hlth Serv, Genet Dis Lab, Richmond, CA 94804 USA
[3] Publ Hlth Inst, Berkeley, CA USA
关键词
newborn screening; tandem mass spectrometry; program implementation;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE. In response to a California legislative mandate, a pilot tandem mass spectrometry (MS/MS) screening program was undertaken by the Genetic Disease Branch of the California Department of Health Services between January 2002 and June 2003. This article outlines the Genetic Disease Branch approach to implementing the MS/MS pilot program and the program evaluation strategies used. METHODS. Through the use of multiple data collection methods, we were able to describe hospital participation patterns, screening test uptake, screening test performance, follow-up services utilization, and provider and family satisfaction with the educational materials and follow-up services provided. RESULTS. During the 18-month pilot program, just more than one half of California's 755 698 newborns were offered MS/MS screening; among this group, 90% of parents chose to have their newborns screened. Fifty-one newborns were identified with MS/MS-detectable disorders, among 461 patients referred for follow-up testing (0.13% of the screened population). One disorder was diagnosed successfully for every 6939 newborns screened and for every 9 infants referred ( excluding phenylketonuria). The overall California population prevalence of MS/MS-detectable disorders was 1 case per 6500 infants ( excluding phenylketonuria). The positive predictive value for medium-chain acyl-CoA dehydrogenase deficiency was 86.7%, whereas the positive predictive value for short-chain acyl-CoA dehydrogenase deficiency was 21.6%. For a sample from Hawaii, 1 isovaleric aciduria case was detected among 6132 newborns. CONCLUSIONS. Evaluation of the California MS/MS screening pilot program demonstrated that this technology was effective in identifying additional metabolic disorders. The positive predictive value of screening was particularly good for medium-chain acyl-CoA dehydrogenase deficiency. Overall, patient referral rates were very acceptable. The utility of the program was also demonstrated by positive reviews from patients and providers.
引用
收藏
页码:S261 / S269
页数:9
相关论文
共 50 条
  • [21] Economic evaluation of tandem mass spectrometry screening in California
    Feuchtbaum, L
    Cunningham, G
    PEDIATRICS, 2006, 117 (05) : S280 - S286
  • [22] Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry: Experience of the Pilot Study in Andhra Pradesh, India
    Sahai, Inderneel
    Zytkowicz, Thomas
    Kotthuri, Srimannarayna Rao
    Kotthuri, Anantha Lakshmi
    Eaton, Roger B.
    Akella, Radha Rama Devi
    INDIAN JOURNAL OF PEDIATRICS, 2011, 78 (08) : 953 - 960
  • [23] Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry: Experience of the Pilot Study in Andhra Pradesh, India
    Inderneel Sahai
    Thomas Zytkowicz
    Srimannarayna Rao Kotthuri
    Anantha Lakshmi Kotthuri
    Roger B. Eaton
    Radha Rama Devi Akella
    The Indian Journal of Pediatrics, 2011, 78 : 953 - 960
  • [24] PILOT RESEARCH ON EXPANDING SLOVENIAN NEWBORN SCREENING PROGRAMME FOR INHERITED METABOLIC DISORDERS DETECTABLE BY TANDEM MASS SPECTROMETRY
    Smon, Andraz
    Murko, Simona
    Lampret, Barbka Repic
    Battelino, Tadej
    CHEMICKE LISTY, 2014, 108 : S183 - S186
  • [25] Successful Implementation of Expanded Newborn Screening in the Philippines Using Tandem Mass Spectrometry
    Padilla, Carmencita D.
    Therrell Jr, Bradford L.
    Alcausin, Maria Melanie Liberty B.
    Chiong, Mary Anne D.
    Abacan, Mary Ann R.
    Reyes, Ma Elouisa L.
    Jomento, Charity M.
    Dizon-Escoreal, Maria Truda T.
    Canlas, Margarita Aziza E.
    Abadingo, Michelle E.
    Posecion, J. Edgar Winston C.
    Abarquez, Conchita G.
    Andal, Alma P.
    Elizaga, Anna Lea G.
    Halili-Mendoza, Bernadette C.
    Otayza, Maria Paz Virginia K.
    Millington, David S.
    INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2022, 8 (01)
  • [26] Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program
    Shafer, FE
    Lorey, F
    Cunningham, GC
    Klumpp, C
    Vichinsky, E
    Lubin, B
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1996, 18 (01) : 36 - 41
  • [27] Newborn screening for sickle cell disorders using tandem mass spectrometry: three years' experience of using a protocol to detect only the disease states
    Moat, Stuart J.
    Rees, Derek
    George, Roanna S.
    King, Lawrence
    Dodd, Alan
    Ifederu, Adeboye
    Ramgoolam, Tejswurree
    Hillier, Sharon
    ANNALS OF CLINICAL BIOCHEMISTRY, 2017, 54 (05) : 601 - 611
  • [28] Newborn Screening for Methylmalonic Aciduria by Tandem Mass Spectrometry: 7 Years' Experience From Two Centers in Taiwan
    Cheng, Kang-Hsiang
    Liu, Mei-Ying
    Kao, Chuan-Hong
    Chen, Yann-Jang
    Hsiao, Kwang-Jen
    Liu, Tze-Tze
    Lin, Hsiang-Yu
    Huang, Cheng-Hung
    Chiang, Chuan-Chi
    Ho, Huey-Jane
    Lin, Shuan-Pei
    Lee, Ni-Chung
    Hwu, Wuh-Liang
    Lin, Ju-Li
    Hung, Ping-Yao
    Niu, Dau-Ming
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2010, 73 (06) : 314 - 318
  • [29] A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing
    Chace, DH
    Kalas, TA
    CLINICAL BIOCHEMISTRY, 2005, 38 (04) : 296 - 309
  • [30] Implementing steroid profiling by liquid chromatography-tandem mass spectrometry improves newborn screening for congenital adrenal hyperplasia in New Zealand
    de Hora, Mark R.
    Heather, Natasha L.
    Patel, Tejal
    Bresnahan, Lauren G.
    Webster, Dianne
    Hofman, Paul L.
    CLINICAL ENDOCRINOLOGY, 2021, 94 (06) : 904 - 912